PMID: 9546119Apr 18, 1998Paper

Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication

Helicobacter
Gerhard TreiberU Klotz

Abstract

Triple therapy regimens including two antibiotics plus acid suppression have become the new standard therapy in Helicobacter pylori eradication because of success rates of about 90%. However, these regimens are still costly, duration is about one week or less, and side-effects are not negligible. We therefore evaluated a new quadruple therapy, because theoretically a shorter duration of treatment may result in reduced costs, fewer side-effects, and possibly in a lower potential for antibiotic resistances. Controlled, prospective pilot study including H. pylori-positive patients with gastric or duodenal ulcers or erosive gastritis, treated after failure of dual therapy (proton-pump-inhibitors or ranitidine plus amoxicillin) or for the first time. They were assigned to a one week triple standard therapy, consisting of metronidazole 400 mg bid + omeprazole 20 mg bid + clarithromycin 250 mg bid, or a newly created quadruple-regimen, which adds amoxicillin (1 g bid) to the above triple regimen. Each of the four drugs was given for 5 days. H. pylori status was checked by 13C urea breath test before and after four weeks of therapy. A total of 71 patients were treated by quadruple therapy, and 42 patients were treated by triple therapy...Continue Reading

References

Feb 7, 1994·NIH Consensus Statement
Jan 1, 1995·Scandinavian Journal of Gastroenterology. Supplement·J S Dixon
Dec 1, 1995·Alimentary Pharmacology & Therapeutics·W A De BoerG N Tytgat
Mar 1, 1997·British Journal of Clinical Pharmacology·J G Penston, K E McColl
Aug 1, 1997·Alimentary Pharmacology & Therapeutics·G TreiberU Klotz

❮ Previous
Next ❯

Citations

Jan 9, 2003·Lancet·Luca Mascitelli, Francesca Pezzetta
May 1, 2008·Nature Clinical Practice. Gastroenterology & Hepatology·David Y Graham, Akiko Shiotani
Jul 4, 2009·Nature Reviews. Gastroenterology & Hepatology·Javier P Gisbert
Jun 26, 1999·Alimentary Pharmacology & Therapeutics·M OkadaT Takata
Sep 1, 1999·Alimentary Pharmacology & Therapeutics·G TreiberU Klotz
Jan 10, 2003·Journal of Gastroenterology and Hepatology·Reza MalekzadehAli Majidpour
Aug 31, 2013·Acta Crystallographica. Section F, Structural Biology and Crystallization Communications·Joyanta K Modak, Anna Roujeinikova
Mar 30, 2012·Clinical and Experimental Gastroenterology·Javier P Gisbert, Xavier Calvet
Dec 24, 2013·World Journal of Gastroenterology : WJG·Enzo IerardiMariabeatrice Principi
May 17, 2014·World Journal of Gastroenterology : WJG·Chang Seok Bang, Gwang Ho Baik
May 17, 2014·World Journal of Gastroenterology : WJG·Jyh-Chin YangChun-Jung Lin
Aug 14, 2012·Gastroenterology Research and Practice·Sung-Shuo KaoFeng-Woei Tsay
Aug 19, 2014·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Jun HeoUNKNOWN Daegu-Gyeongbuk Gastrointestinal Study Group
Sep 4, 2015·Expert Opinion on Pharmacotherapy·Sotirios D GeorgopoulosStylianos Karatapanis
Jan 22, 2013·Expert Opinion on Pharmacotherapy·Sotirios D GeorgopoulosStylianos Karatapanis
Mar 9, 2010·Expert Opinion on Pharmacotherapy·Javier P GisbertColm A O'Morain
Jun 12, 2013·Clinics and Research in Hepatology and Gastroenterology·Angelo ZulloPiero Portincasa
Oct 7, 2009·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Deng-Chyang WuDavid Y Graham
Aug 2, 2006·Gastroenterology Clinics of North America·Ratha-Korn VilaichoneDavid Y Graham
Aug 3, 2007·Helicobacter·David Y GrahamYoshio Yamaoka
Jul 13, 2011·Alimentary Pharmacology & Therapeutics·J P Gisbert, X Calvet
Mar 5, 2015·Alimentary Pharmacology & Therapeutics·J Molina-InfanteJ P Gisbert
Mar 23, 2010·Helicobacter·Masahiro AsakaUNKNOWN Japanese Society for Helicobacter Research
May 16, 2006·Gastroenterology·David Y Graham, Hong Lu
Aug 31, 2010·Journal of Zhejiang University. Science. B·Ning ZhouYou-ming Li
Jun 20, 2015·BioMed Research International·Guang-Hong JhengPing-I Hsu
Jan 8, 2010·Journal of Clinical Gastroenterology·Javier P GisbertColm A O'Morain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.